Dystrophic Epidermolysis Bullosa
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Dystrophic Epidermolysis Bullosa

What is the definition of Dystrophic Epidermolysis Bullosa?

Dystrophic epidermolysis bullosa is one of the major forms of a group of conditions called epidermolysis bullosa. Epidermolysis bullosa cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. The signs and symptoms of dystrophic epidermolysis bullosa vary widely among affected individuals. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases of this condition involve widespread blistering that can lead to vision loss, scarring, and other serious medical problems.

What are the causes of Dystrophic Epidermolysis Bullosa?

Mutations in the COL7A1 gene cause all forms of dystrophic epidermolysis bullosa. This gene provides instructions for making a protein that forms the pieces (subunits) of a larger protein called type VII collagen. Collagens are proteins that give structure and strength to connective tissues, such as skin, tendons, and ligaments, throughout the body. Type VII collagen plays an important role in strengthening and stabilizing the skin. It is the main component of structures called anchoring fibrils, which anchor the top layer of skin, called the epidermis, to an underlying layer called the dermis.

How prevalent is Dystrophic Epidermolysis Bullosa?

Considered together, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated to be 3.3 per million people.

Is Dystrophic Epidermolysis Bullosa an inherited disorder?

Recessive dystrophic epidermolysis bullosa (RDEB-sev gen and RDEB-gen and -loc) is inherited in an autosomal recessive pattern. Autosomal recessive inheritance means that both copies of the COL7A1 gene in each cell have mutations. Most often, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but do not show signs and symptoms of the condition.

Who are the top Dystrophic Epidermolysis Bullosa Local Doctors?
Elite in Dystrophic Epidermolysis Bullosa
Elite in Dystrophic Epidermolysis Bullosa

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
Languages Spoken:
English

Anna Bruckner is a Pediatrics provider in Aurora, Colorado. Dr. Bruckner is rated as an Elite provider by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. Her top areas of expertise are Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa.

Elite in Dystrophic Epidermolysis Bullosa
Dermatology
Elite in Dystrophic Epidermolysis Bullosa
Dermatology

Dermatologists Of Southwest Ohio, Inc.

7691 5 Mile Road, Suite 312, 
Cincinnati, OH 
Languages Spoken:
English
Accepting New Patients

Anne Lucky is a Dermatologist in Cincinnati, Ohio. Dr. Lucky is rated as an Elite provider by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. Her top areas of expertise are Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa. Dr. Lucky is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Dystrophic Epidermolysis Bullosa
Elite in Dystrophic Epidermolysis Bullosa
Hugstetter Str. 55, 
Freiburg, BW, DE 

Alexander Nystrom practices in Freiburg, Germany. Mr. Nystrom is rated as an Elite expert by MediFind in the treatment of Dystrophic Epidermolysis Bullosa. His top areas of expertise are Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, and Epidermolysis Bullosa Simplex.

What are the latest Dystrophic Epidermolysis Bullosa Clinical Trials?
Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis Bullosa

Summary: The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa

Summary: This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, a pair of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.

Who are the sources who wrote this article ?

Published Date: February 01, 2020
Published By: National Institutes of Health